金石亚药(300434.SZ)：双氯芬酸钠缓释片通过仿制药一致性评价

Core Viewpoint - Kingstone Pharmaceuticals (300434.SZ) announced that its wholly-owned subsidiary, Zhejiang Deer Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for its Diclofenac Sodium Sustained-release Tablets (0.1g) after passing the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approved Diclofenac Sodium Sustained-release Tablets are indicated for the relief of various chronic arthritis conditions, including rheumatoid arthritis, osteoarthritis, spondyloarthritis, gouty arthritis, and rheumatic arthritis during acute episodes or persistent joint pain [1] - The product is also indicated for various soft tissue rheumatic pains such as shoulder pain, tenosynovitis, bursitis, myalgia, and pain from sports injuries [1] - Additionally, it is indicated for acute mild to moderate pain, including pain following surgery, trauma, or strain, as well as primary dysmenorrhea, toothache, and headache [1]